<code id='73FBAFAA9B'></code><style id='73FBAFAA9B'></style>
    • <acronym id='73FBAFAA9B'></acronym>
      <center id='73FBAFAA9B'><center id='73FBAFAA9B'><tfoot id='73FBAFAA9B'></tfoot></center><abbr id='73FBAFAA9B'><dir id='73FBAFAA9B'><tfoot id='73FBAFAA9B'></tfoot><noframes id='73FBAFAA9B'>

    • <optgroup id='73FBAFAA9B'><strike id='73FBAFAA9B'><sup id='73FBAFAA9B'></sup></strike><code id='73FBAFAA9B'></code></optgroup>
        1. <b id='73FBAFAA9B'><label id='73FBAFAA9B'><select id='73FBAFAA9B'><dt id='73FBAFAA9B'><span id='73FBAFAA9B'></span></dt></select></label></b><u id='73FBAFAA9B'></u>
          <i id='73FBAFAA9B'><strike id='73FBAFAA9B'><tt id='73FBAFAA9B'><pre id='73FBAFAA9B'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:focus    Page View:5
          People taking notes while sitting around a meeting table
          Adobe

          It makes sense in theory for hospitals and startups to strike deals. Not only would doctors get first dibs on new health care technologies, their organizations would see windfalls if those startups hit it big.

          In practice, it often doesn’t work out that way. Doctors and other clinicians have their own way of doing things, and they typically don’t take kindly to an administrator telling them to learn a new product, especially if the goal is financial gain.

          advertisement

          Several health system-venture capital arrangements have fallen victim to this dynamic — but VC firm General Catalyst said this week it will buy nonprofit Summa Health, anyway.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          FDA approves first new drug developed for postpartum depression
          FDA approves first new drug developed for postpartum depression

          AdobeTheFoodandDrugAdministrationonTuesdayapprovedbrexanolone,thefirstdrugspecificallytargetedtotrea

          read more
          Medical leaders decry Supreme Court decision on affirmative action
          Medical leaders decry Supreme Court decision on affirmative action

          STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

          read more

          Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

          JustinSullivan/GettyImagesWhenpeoplemisrepresentfactsontherecord,journalistsareinatoughspot—especial